Replication-defective herpes simplex virus mutant strains as genital herpes vaccines and vaccine vectors

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 285-298

  Knipe, David M ^a   Knipe, D M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; HERPEVAC; HERPEVAC VACCINE; IMMUNOVEX; IMMUNOVEX VACCINE; UNCLASSIFIED DRUG;

AMPLICON; CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; GENETIC VARIABILITY; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 1 INFECTION; HERPES SIMPLEX VIRUS 2; HERPES SIMPLEX VIRUS 2 INFECTION; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 79960030795     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0277-8_12     Document Type: Review

References (68)

1. Roizman B, Knipe DM, Whitley RJ (2007) Herpes simplex virus. In: Knipe DM, Howley PM (eds) Fields Virology, 5th ed. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 2501-2602
2. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 20:73-83
3. Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185:45-52
4. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, Defer MC, Djagbare D, Sanon A, Andonaba JB et al (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356:790-799
5. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebocontrolled, cross-over trial. J Infect Dis 198:1804-1808
6. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J et al (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebocontrolled trial. Lancet 371:2109-2119
7. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, Tanton C, Ross D, Everett D, Clayton T et al (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358:1560-1571
8. Stanberry LR (1995) Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol 3:244-247
9. Whitley RJ (1993) Prospects for vaccination against herpes simplex virus. Pediatr Ann 22:726-732
10. Aurelian L, Kokuba H, Smith CC (1999) Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17:1951-1963
11. Wachsman M, Kulka M, Smith CC, Aurelian L (2001) A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19:1879-1890
12. Casanova G, Cancela R, Alonzo L, Benuto R, Magana Mdel C, Hurley DR, Fishbein E, Lara C, Gonzalez T, Ponce R et al (2002) A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 70:235-239
13. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM (2008) A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J Virol 82:8431-8441
14. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S et al (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group. JAMA 28:331-340
15. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF et al (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463
16. Straus SE, Wald A, Kost RG et al (1997) Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebocontrolled vaccine trial. J Infect Dis 176:1129-1134
17. Stanberry LR, Spruance SL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P et al (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347:1652-1661
18. Koelle DM, Corey L (2003) Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16:96-113
19. Nguyen LH, Knipe DM, Finberg RW (1992) Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 66: 7067-7072
20. Da Costa XJ, Bourne N, Stanberry LR, Knipe DM (1997) Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital herpes. Virology 232:1-12
21. Godowski PJ, Knipe DM (1985) Identification of a herpes simplex virus function that represses late gene expression from parental viral genomes. J Virol 55:357-365
22. Da Costa XJ, Jones CA, Knipe DM (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 96: 6994-6998
23. Da Costa XJ, Kramer MF, Zhu J, Brockman MA, Knipe DM (2000) Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74:7963-7971
24. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE (2005) Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79:410-418
25. Morrison LA, Knipe DM (1994) Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J Virol 68:689-696
26. Dudek T, Mathews LC, Knipe DM (2008) Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 372:165-175
27. Storer JB (1966) Longevity and gross pathology at death in 22 inbred strains of mice. J Gerontol 21:404-409
28. Brockman MA, Verschoor A, Zhu J, Carroll MC, Knipe DM (2006) Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol 80:7111-7117
29. Morrison LA (2008) Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 376:205-210
30. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI (2008) Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034-4040
31. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200:1088-1095
32. Morrison LA, Da Costa XJ, Knipe DM (1998) Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243:178-187
33. Malkin JE (2004) Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 11(Suppl 1):2A-23A
34. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973
35. van Lint AL, Torres-Lopez E, Knipe DM (2007) Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 368:227-231
36. Forrester A, Farrell H, Wilkinson G, Kaye J, Davis-Poynter N, Minson T (1992) Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol 66:341-348
37. Farrell HE, McLean CS, Efstathlou S, Inglls S, Minson AC (1994) Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 68: 927-932
38. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC (1994) Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a geneitcally disabled HSV-1. J Infect Dis 170:1100-1109
39. Loudon PT, Blakeley DM, Boursnell ME, Day DA, Duncan IA, Lowden RC, McLean CS, Martin G, Miller JC, Shaw ML (2001) Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients. J Gene Med 3:458-467
40. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR et al (2006) A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24:914-920
41. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC (1994) Acytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77:525-535
42. Read GS, Frenkel N (1983) Herpes simplex virus mutants defective in the virion-associated shutoff of host polypeptide synthesis and exhibiting abnormal synthesis of alpha (immediate early) viral polypeptides. J Virol 46:498-512
43. Taddeo B, Roizman B (2006) The virion host shutoff protein (UL41) of herpes simplex virus 1 is an endoribonuclease with a substrate specificity similar to that of RNase A. J Virol 80: 9341-9345
44. He B, Gross M, Roizman B (1997) The gamma (1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94:843-848
45. Melroe G, DeLuca N, Knipe DM (2004) Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J Virol 78:8411-8420
46. Liang L, Roizman B (2008) Expression of gamma interferon-dependent genes is blocked independently by virion host shutoff RNase and by US3 protein kinase. J Virol 82:4688-4696
47. Reszka NJ, Zhou C, Song B, Sodroski JG, Knipe DM (2010) Simian TRIM5a proteins reduce replication of herpes simplex virus. Virology 398:243-250
48. Walker J, Leib DA (1998) Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine 16:1-5
49. Geiss BJ, Smith TJ, Leib DA, Morrison LA (2000) Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. J Virol 74:11137-11144
50. Reszka NJ, Dudek T, Knipe DM (2010) Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28(15): 2754-62
51. Vagvala SP, Thebeau LG, Wilson SR, Morrison LA (2009) Virus-encoded B7-2 costimulation molecules enhance the protective capacity of a replication-defective HSV-2 vaccine in immunocompetent mice. J Virol 83:953-960
52. Mbizvo MT, Mashu A, Chipato T, Makura E, Bopoto R, Fottrell PF (1996) Trends in HIV-1 and HIV-2 prevalence and risk factors in pregnant women in Harare, Zimbabwe. Cent Afr J Med 42:14-21
53. Greenblatt RM, Lukehart SA, Plummer FA, Quinn TC, Critchlow CW, Ashley RL, D'Costa LJ, Ndinya-Achola JO, Corey L, Ronald AR et al (1988) Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 2:47-50
54. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, Ndinya-Achola J, Bwayo JJ, Corey L (2000) Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 181:58-63
55. Norberg P, Kasubi MJ, Haarr L, Bergstrom T, Liljeqvist JA (2007) Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 81:13158-13167
56. Knipe DM, Ruyechan WT, Roizman B, Halliburton IW (1978) Molecular genetics of herpes simplex virus: demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion. Proc Natl Acad Sci USA 75:3896-3900
57. Brubaker JO, Thompson CM, Morrison LA, Knipe DM, Siber GB, Finberg RW (1996) Th1-associated immune responses to beta-galactosidase expressed by replication-defective herpes simplex virus. J Immunol 157:1598-1604
58. Murphy CG, Lucas WT, Means R, Czajak S, Hale CL, Lifson JD, Kauer A, Johnson RP, Knipe DM, Desrosiers RC (2000) Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 74:7745-7754
59. Watanabe D, Brockman MA, Ndung'u T, Mathews L, Lucas WT, Murphy CG, Felber BK, Pavlakis GN, Deluca NA, Knipe DM (2007) Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology 357:186-198
60. Kaur A, Sanford HB, Garry D, Lang S, Klumpp SA, Watanabe D, Bronson RT, Lifson JD, Rosati M, Pavlakis GN et al (2007) Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 357:199-214
61. Liu X, Broberg E, Watanabe D, Dudek T, DeLuca N, Knipe DM (2009) Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 27:2760-2767
62. Spaete RR, Frenkel N (1982) The herpes simplex virus amplicon: a new eucaryotic defectivevirus cloning-amplifying vector. Cell 30:295-304
63. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI (1996) Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 70:7190-7197
64. Hocknell PK, Wiley RD, Wang X, Evans TG, Bowers WJ, Hanke T, Federoff HJ, Dewhurst S (2002) Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 76:5565-5580
65. Duke CM, Maguire CA, Keefer MC, Federoff HJ, Bowers WJ, Dewhurst S (2007) HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 25:7410-7421
66. Cliffe AR, Knipe DM (2008) Herpes simplex virus ICP0 promotes both histone removal and acetylation on viral DNA during lytic infection. J Virol 82:12030-12038
67. Suzuki M, Kasai K, Ohtsuki A, Godlewski J, Nowicki MO, Chiocca EA, Saeki Y (2009) ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression. Mol Ther 17:705-715
68. van Lint A, Murawski MR, Goodbody RE, Severa M, Fitzgerald KA, Finberg RW, Knipe DM, Kurt-Jones EA (2010) Herpes simplex virus immediate-early ICP0 protein inhibits TLR2-dependent inflammatory responses and NF-kB signaling. J Virol epublished PMID 20686034.